About Us: Laboratory for Functional Precision Medicine
Given the rapid development of new small molecule cancer therapeutics, there is a growing need for predictive diagnostics to match cancer patients with optimal therapies. Unfortunately, molecular changes induced by cancer therapies are complex, and for most patients we cannot accurately predict tumor response based on pretreatment genomic or proteomic measurements. We previously developed a precision medicine technology with a functional phenotypic readout called dynamic BH3 profiling (DBP). DBP exposes cancer cells to drugs and measures induction of apoptotic cell death signaling after 24 hours ex vivo. We previously performed proof of principle tests using large excisional tumor samples and demonstrated that DBP predicts chemotherapy response in animal models and humans.
The Laboratory for Functional Precision Medicine (LFPM) is a small lab space within the Laboratory for Systems Pharmacology to perform dynamic BH3 Profiling. The goal is to use dynamic BH3 Profiling for identifying drug treatments for cancer types (with a focus on solid tumors), and for precision medicine:
HT-DBP screens on colon cancer, pancreatic cancer, fibrolamellar hepatocellular carcinoma, sarcoma, ovarian cancer, rapid autopsy tumors, and canine cancers.